Abstract: The invention relates to a pharmacological composition comprising a polyelectrolyte complex, in particular a polyacid with an average particle size of less than 15 .mu.m and an active agent, among which are active peptides, proteins, enzymes, enzyme inhibitors, antigens, cytostatics, antiinflamatory agents, antibiotics and vaccines. The said composition ensures that the active agent is converted in a non-deleterious manner into a form which can be administered. In addition, the biodistribution, bioavailability and absorption of the pharmaceutical are beneficially affected.

Abstract: Polycondensates which contain tartaric acid derivatives, processes for their preparation and use thereof.The invention relates to polycondensates which consist of at least 95 mol % of recurring structural units of the formula I ##STR1## where R.sup.1 is a 2,3-O-alkylidenetartaric acid derivative (II) or furo[2,5] (V), alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, X is --O-- --NH-- or --S-- and R.sup.2 is 2,3-O-alkylidene-L-threitol (III) or a compound of the formula VI, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, with the proviso that more than 5 mol % of the radicals R.sup.1 and/or R.sup.2 are present in the polycondensate of the formula I, where R.sup.1 is compound of the formula II or R.sup.2 is a compound of the formula III or R.sup.1 is a compound of the formula II and R.sup.2 is a compound of the formula III, or in which more than 5 mol % of the radicals R.sup.1 and R.sup.2 are present in the polycondensate of the formula I, wherea) R.sup.

Abstract: The invention relates to polycondensates which consist of at least 95 mol % of recurring structural units of the formula I ##STR1## where R.sup.1 is a 2,3-O-alkylidenetartaric acid derivative (II) or furo[2,5] (V), alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, X is --O--, --NH-- or --S-- and R.sup.2 is 2,3-O-alkylidene-L-threitol (III) or a compound of the formula VI, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, with the proviso that more than 5 mol % of the radicals R.sup.1 and/or R.sup.2 are present in the polycondensate of the formula I, where R.sup.1 is compound of the formula II or R.sup.2 is a compound of the formula III or R.sup.1 is a compound of the formula II and R.sup.2 is a compound of the formula III, or in which more than 5 mol % of the radicals R.sup.1 and R.sup.2 are present in the polycondensate of the formula I, wherea) R.sup.1 is a compound of the formula V and R.sup.2 is a compound of the formula VI, orb) R.sup.

Abstract: The invention is a chelate of formula I: ##STR1## wherein R.sub.1-4 is --CH.sub.2 COOH;n is 1 to 5;X is a member selected from the group consisting of--NO.sub.2,--NH.sub.2,--NCS,--NHCOCH.sub.2 --Z, with Z being a member selected from the group consisting of Br and I,--COOH; and--OCH.sub.2 OOCH;and M is a metal ion selected from the group of elements consisting ofBi, Pb, Y, Cd, Hg, Al, Th, Sr, and Lanthanides.The invention also includes a chelate, wherein M is a copper ion and n is an integer from 2 to 5. The invention includes chelate conjugates of formula I and ligand conjugates of formula II: ##STR2## The invention also includes methods to use these compounds for treatment of cellular disorders and for diagnostic tests.

Abstract: Polycondensates which contain tartaric acid derivatives, processes for their preparation and use thereof.The invention relates to polycondensates which consist of at least 95 mol % of recurring structural units of the formula I ##STR1## where R.sup.1 is a 2,3-O-alkylidenetartaric acid derivative (II) or furo[2,5] (V), alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, X is --O--, --NH-- or --S-- and R.sup.2 is 2,3-O-alkylidene-L-threitol (III) or a compound of the formula VI, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, with the proviso that more than 5 mol % of the radicals R.sup.1 and/or R.sup.2 are present in the polycondensate of the formula I, where R.sup.1 is compound of the formula II or R.sup.2 is a compound of the formula III or R.sup.1 is a compound of the formula II and R.sup.2 is a compound of the formula III, or in which more than 5 mol % of the radicals R.sup.1 and R.sup.2 are present in the polycondensate of the formula I, wherea) R.sup.

Abstract: A liquid-crystalline mixture comprising at least two components, the first being an aromatic mercapto compound of the formula (I) ##STR1## R.sup.1, R.sup.2, R.sup.3 and R.sup.4, independently of one another, are hydrogen, alkyl having 1 to 8 carbon atoms or alkoxy having 1 to 8 carbon atoms,--X-- is --O--, --S-- or --NH--,k and m, independently of one another, are 1, 2, or 3, andl is zero or 1, results in high contrasts in electrooptical switching and display devices.

Abstract: The invention relates to a method for labeling substances with--in particular radioactive--technetium or rhenium isotopes with the aid of N-substituted or C-substituted macrocyclic amine derivatives of the formula I and/or II ##STR1## in which R.sup.1 -R.sup.7, Y, m, n, o, p, f, g, h, i and j have the stated meanings, and to the use of these labeled substances, especially in medical diagnosis.

Abstract: The invention relates to ultrasonic contrast agents composed of microparticles which contain a gas and polyamino-dicarboxylic acid-co-imide derivatives, to processes for their preparation and to their use as diagnostic and therapeutic agents.

Abstract: The invention relates to ultrasonic contrast agents composed of microparticles which contain a gas and polyamino-dicarboxylic acid-co-imide derivatives, to processes for their preparation and to their use as diagnostic and therapeutic agents.

Abstract: The invention relates to ultrasonic contrast agents composed of microparticles which contain a gas and polyamino-dicarboxylic acid-co-imide derivatives, to processes for their preparation and to their use as diagnostic and therapeutic agents.

Abstract: A cofactor having an aromatic or benzylic amino group is converted into an isothiocyanate by reaction with a compound such as thiophosgene and the isothiocyanate of the cofactor is attached to a polymer which is preferably water-soluble. When the polymer has amino groups, a thiourea bridge is formed between the polymer and cofactor and a polymer having hydroxyl groups results in a thiocarbamate bridge. The polymer may be a copolymer of vinylamine or vinylmethylamine and vinylmethylacetamide, partially alkylamine-substituted .alpha., .beta.-poly-(2-hydroxyethyl)-D,L-aspartamide, polyethyleneimine or carbohydrate. The cofactor bound to a polymer and an enzyme are contained in microcapsules or in a membrane to form an enzyme reactor.

Abstract: Polyamides in which amino acids are incorporated in the polymer backbone via two amino or carboxyl groups and which carry in the .alpha.-position to the amide structure a functional group which is responsible for degradation and active compound release are highly suitable for the preparation of biologically degradable active compound depot preparations having controlled release of the active compound.